[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"exudative-age-related-macular-degeneration\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:exudative-age-related-macular-degeneration":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,4,0,[8,39,61,89],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":28,"startDateStruct":31,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100625499","study-of-switching-to-aflibercept-8-mg-in-patients-with-refractory-or-dependent-exudative-age-related-macular-degeneration-100625499",false,"NCT07423429","Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration","Retrospective Multicenter Real-world Observational Study of Switching to Aflibercept 8 mg in Patients With Refractory or Dependent Exudative Age-related Macular Degeneration","AFLIWEST","Inclusion Criteria:\n\n* Adults (≥18 years) with exudative (neovascular) age-related macular degeneration\n* Treated with intravitreal anti-VEGF therapy for more than 1 year\n* Switched to aflibercept 8 mg before July 31, 2025\n* Injection interval strictly less than 12 weeks prior to switch\n\nExclusion Criteria:\n\n* High myopia (axial length \\> 26 mm or spherical equivalent \\\u003C -6 diopters)\n* Angioid streaks\n* Moderate or severe diabetic retinopathy\n* History of diabetic macular edema\n* History of uveitis\n* History of retinal vein occlusion (branch or central)\n* History of pseudovitelliform macular dystrophy\n* Patient under legal guardianship or curatorship\n* Pregnant or breastfeeding women","ALL","18 Years",{"count":20,"type":21},100,"ESTIMATED","OBSERVATIONAL","Age-related macular degeneration is a leading cause of visual impairment in older adults. In its exudative form, repeated intravitreal injections of anti-VEGF agents are required to control disease activity. A new formulation of aflibercept at a higher dose (8 mg) has been developed with the aim of extending the interval between injections.\n\nThis multicenter retrospective real-world observational study will evaluate the effect of switching to aflibercept 8 mg in patients with refractory or dependent exudative age-related macular degeneration. Clinical data collected during routine care will be analyzed to compare injection intervals, treatment burden, visual outcomes, anatomical outcomes, and safety before and after the switch.",[25],"Exudative Age-Related Macular Degeneration","RECRUITING","2026-06-23",{"date":29,"type":30},"2026-06-25","ACTUAL",{"date":32,"type":30},"2026-02-20",{"date":34,"type":21},"2026-10-20",{"name":36,"class":37},"Nantes University Hospital","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":44,"acronym":4,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":46,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":48,"conditions":49,"keywords":51,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":27,"lastUpdatePostDateStruct":54,"startDateStruct":56,"completionDateStruct":58,"leadSponsor":60,"locationsCount":38},"100593278","ethical-issues-of-using-gene-therapy-in-the-treatment-of-amd-100593278","NCT07004361","Ethical Issues of Using Gene Therapy in the Treatment of AMD","Ethical Issues of Using Gene Therapy in the Treatment of AMD (Age-related Macular Degeneration)","Inclusion Criteria:\n\n* Patients with exsudative AMD, male female \\>18 years Patients for whom the doctor could consider gene therapy.\n\nExclusion Criteria:\n\nPatients with atrophic AMD (Age-related Macular Degeneration) Patients with other degenerative retinal diseases than AMD, Patients with with associated cognitive disorders.",{"count":47,"type":21},30,"The objective of this study is to examine the legitimacy of gene therapy use in the treatment of exudative age-related macular degeneration (AMD). This involves questioning its beneficence\u002Fnon-maleficence ratio given the limited experience with this innovative technology and its irreversible effects, requiring a surgical procedure for administration. Additionally, the study explores patient autonomy in decision-making concerning complex therapeutic approaches and how patients should be supported to best uphold this autonomy.",[50],"Exudative Age-related Macular Degeneration",[52,53],"ethical","Age-related Macular Degeneration",{"date":55,"type":30},"2026-06-24",{"date":57,"type":30},"2025-07-01",{"date":59,"type":21},"2026-12",{"name":36,"class":37},{"id":62,"slug":63,"hasResults":11,"nctId":64,"briefTitle":65,"officialTitle":65,"acronym":66,"eligibilityCriteria":67,"healthyVolunteers":11,"sex":17,"minAge":68,"maxAge":4,"enrollmentInfo":69,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":71,"conditions":72,"keywords":73,"overallStatus":78,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":88},"100619111","home-monitoring-in-eamd-treatment-100619111","NCT07340372","Home Monitoring in eAMD Treatment","HOME","Inclusion Criteria:\n\n* Adults (≥ 55 years old) with exudative AMD in the study eye.\n* Treatment-naïve patients or patients who have started treatment with IVT anti-VEGF (aflibercept 2 mg, aflibercept 8 mg, faricimab, ranibizumab, bevacizumab, brolucizumab, pegaptanib sodium) up to 48 weeks before inclusion.\n* BCVA early treatment diabetic retinopathy study (ETDRS) letter score of 85 to 34 (approximate Snellen equivalent of 20\u002F20 to 20\u002F200) in the study eye with decreased vision determined to be primarily the result of eAMD.\n* Willing and able to comply with clinic visits and study-related procedures.\n* Provide informed consent signed by study participant or legally acceptable representative.\n* Own a working smartphone or tablet compatible with the OKKO Health application.\n* Be able to operate the application after training according to OKKO Health indications of use: be alert and mentally competent, has competent dexterity and has normal or corrected hearing to normal audio level.\n\nExclusion Criteria:\n\n* Evidence of macular edema due to any cause other than eAMD in either eye.\n* Other ocular disease in the study eye that could prevent an accurate evaluation of treatment efficacy like, diabetic macular edema, posterior uveitis, corneal opacity, vein occlusion, macular dystrophy.\n* IVT anti-VEGF or steroid implants (aflibercept, ranibizumab, bevacizumab, brolucizumab, pegaptanib sodium, triamcinolone, dexamethasone, fluocinolone) for more than 1 year before inclusion.\n* Treatment with ocriplasmin (JETREA®) in the study eye at any time.","55 Years",{"count":70,"type":21},80,"The goal of this observational clinical study is to collect more information about the efficacy of Aflibercept 8 mg injections in people with eAMD. The main questions it aims to answer are:\n\n* To reassure patients and doctors with longer intervals using home monitoring app;\n* To assess patient reported outcomes (PROMs) and Value-based Healthcare.\n\nParticipants already taking Aflibercept 8 mg as part of their regular medical care for eAMD will undergo regular ophthalmological examination and use a home monitoring app, in a one year and a two-year treatment period.",[25],[74,25,75,76,77],"Aflibercept 8 mg","Patient reported outcomes","Value-based Healthcare","Home monitoring app","NOT_YET_RECRUITING","2026-05-05",{"date":81,"type":30},"2026-05-06",{"date":83,"type":21},"2026-05",{"date":85,"type":21},"2027-12",{"name":87,"class":37},"Association for Innovation and Biomedical Research on Light and Image",8,{"id":90,"slug":91,"hasResults":11,"nctId":92,"briefTitle":93,"officialTitle":94,"acronym":4,"eligibilityCriteria":95,"healthyVolunteers":11,"sex":17,"minAge":96,"maxAge":97,"enrollmentInfo":98,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":100,"conditions":101,"keywords":104,"overallStatus":26,"whyStopped":4,"lastUpdateSubmitDate":111,"lastUpdatePostDateStruct":112,"startDateStruct":114,"completionDateStruct":116,"leadSponsor":118,"locationsCount":38},"100611049","real-life-clinical-outcomes-of-aflibercept-biosimilar-my-1701p-in-the-treatment-of-exudative-age-related-macular-degeneration-100611049","NCT07235527","Real-Life Clinical Outcomes of Aflibercept Biosimilar MY-1701P in the Treatment of Exudative Age-Related Macular Degeneration","Real-World Outcomes of Aflibercept Biosimilar MY-1701P Treatment in Exudative Age-Related Macular Degeneration","Inclusion Criteria:\n\n* Patients aged between 45 and 90 years with active neovascular age-related macular degeneration (nAMD)\n* who show signs of disease activity on routine ophthalmologic examination and optical coherence tomography (OCT)\n* for whom intravitreal injection has already been clinically indicated\n\nExclusion Criteria:\n\n* Patients younger than 45 years or older than 90 years\n* History of stroke, cerebrovascular event, myocardial infarction, or coronary stent placement within the last six months\n* Presence of uveitis\n* Media opacity preventing adequate retinal imaging (e.g., corneal opacity, mature cataract)\n* Coexistence of other retinal vascular diseases (e.g., branch retinal vein occlusion, diabetic macular edema)\n* Presence of hereditary retinal dystrophies\n* Presence of optic atrophy","45 Years","90 Years",{"count":99,"type":21},54,"In this study, patients receiving Eylea treatment will be treated with Yesafili, a biosimilar molecule, and routine examination results will be noted.",[102,25,103],"Age Related Macular Degeneration","Anti Vascular Endothelial Growth Factor",[105,106,107,108,109,110],"age related macular degeneration","anti vascular endothelial growth factor","anti-VEGF","aflibercept","macular neovascularization","aflibercept biosimilar","2025-12-05",{"date":113,"type":30},"2025-12-08",{"date":115,"type":30},"2025-11-20",{"date":117,"type":21},"2026-08-20",{"name":119,"class":37},"Saglik Bilimleri Universitesi"]